Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerstin Michalski

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Chirurgie (Heidelberg, Germany)|January 29, 2026
[Novel imaging techniques for the differential diagnosis of adrenal tumors, pheochromocytomas and paragangliomas]Friederike Eilsberger, Kerstin Michalski, Markus Luster
Nuklearmedizin. Nuclear Medicine|November 15, 2019
Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapyKerstin Michalski, Michael Mix, Philipp T Meyer, et al.
Plos One|July 18, 2017
Dealing with foreign cultural paradigms: A systematic review on intercultural challenges of international medical graduatesKerstin Michalski, Nabeel Farhan, Edith Motschall, et al.
Geburtshilfe Und Frauenheilkunde|January 14, 2022
Expression of Prostate Specific Membrane Antigen (PSMA) in Breast CancerClara Unger, Peter Bronsert, Kerstin Michalski, et al.
Clinical Nuclear Medicine|May 27, 2022
Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential?Kerstin Michalski, Cordula A Jilg, Monika Engelhardt, et al.
EJNMMI Research|April 11, 2022
Bone marrow impairment during early [<sup>177</sup>Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?Felix Kind, Kerstin Michalski, Elham Yousefzadeh-Nowshahr, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2021
Assessing Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy using modified PSMA PET Progression CriteriaKerstin Michalski, Claudius Klein, Tonio Brueggemann, et al.
Seminars in Nuclear Medicine|June 25, 2023
PSMA PET/CT for Response Assessment of <sup>177</sup>Lu-PSMA TherapyPhilipp E Hartrampf, Sebastian E Serfling, Kerstin Michalski, et al.
Pharmaceuticals (Basel, Switzerland)|January 23, 2024
Radiopharmaceuticals for Treatment of Adrenocortical CarcinomaKerstin Michalski, Wiebke Schlötelburg, Philipp E Hartrampf, et al.
Cancers|December 10, 2021
Gastrin-Releasing Peptide Receptor Antagonist [<sup>68</sup>Ga]RM2 PET/CT for Staging of Pre-Treated, Metastasized Breast CancerKerstin Michalski, Lars Kemna, Jasmin Asberger, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Chirurgie (Heidelberg, Germany)|January 29, 2026
[Novel imaging techniques for the differential diagnosis of adrenal tumors, pheochromocytomas and paragangliomas]Friederike Eilsberger, Kerstin Michalski, Markus Luster
Nuklearmedizin. Nuclear Medicine|November 15, 2019
Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapyKerstin Michalski, Michael Mix, Philipp T Meyer, et al.
Plos One|July 18, 2017
Dealing with foreign cultural paradigms: A systematic review on intercultural challenges of international medical graduatesKerstin Michalski, Nabeel Farhan, Edith Motschall, et al.
Geburtshilfe Und Frauenheilkunde|January 14, 2022
Expression of Prostate Specific Membrane Antigen (PSMA) in Breast CancerClara Unger, Peter Bronsert, Kerstin Michalski, et al.
Clinical Nuclear Medicine|May 27, 2022
Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential?Kerstin Michalski, Cordula A Jilg, Monika Engelhardt, et al.
EJNMMI Research|April 11, 2022
Bone marrow impairment during early [<sup>177</sup>Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?Felix Kind, Kerstin Michalski, Elham Yousefzadeh-Nowshahr, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2021
Assessing Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy using modified PSMA PET Progression CriteriaKerstin Michalski, Claudius Klein, Tonio Brueggemann, et al.
Seminars in Nuclear Medicine|June 25, 2023
PSMA PET/CT for Response Assessment of <sup>177</sup>Lu-PSMA TherapyPhilipp E Hartrampf, Sebastian E Serfling, Kerstin Michalski, et al.
Pharmaceuticals (Basel, Switzerland)|January 23, 2024
Radiopharmaceuticals for Treatment of Adrenocortical CarcinomaKerstin Michalski, Wiebke Schlötelburg, Philipp E Hartrampf, et al.
Cancers|December 10, 2021
Gastrin-Releasing Peptide Receptor Antagonist [<sup>68</sup>Ga]RM2 PET/CT for Staging of Pre-Treated, Metastasized Breast CancerKerstin Michalski, Lars Kemna, Jasmin Asberger, et al.
Pageof 4